Epacria Capital Partners’s ClearPoint Neuro CLPT Stock Holding History

Epacria Capital Partners’s Portfolio CLPT Stock Details CLPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-11,729	Closed	-$107K	–	25
2026 Q1	$107K	Hold	11,729	–	–	0.08%	29
2025 Q4	$160K	Hold	11,729	–	–	0.13%	31
2025 Q3	$256K	Hold	11,729	–	–	0.21%	31
2025 Q2	$140K	Buy	+11,729	New	+$148K	0.12%	33

Other funds holding CLPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MCO

MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Lane Generational Dover, Massachusetts $114M AUM 43.8% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

CFM

Compass Financial Management Tampa, Florida $829M AUM

Epacria Capital Partners's CLPT Position: Q2 2026 in Review

Epacria Capital Partners sold out of ClearPoint Neuro (CLPT) in Q2 2026, closing a stake of 11,729 shares — an estimated $107K sold.

Epacria Capital Partners first reported a position in CLPT in Q2 2025 and held it in 4 quarters. The position peaked at $256K in Q3 2025. 128 funds tracked by Wall St. Rank hold CLPT as of Q2 2026.

Epacria Capital Partners reported no remaining ClearPoint Neuro position as of Q2 2026 after selling out during the quarter.
Epacria Capital Partners sold 11,729 ClearPoint Neuro shares in Q2 2026, an estimated $107K.
Epacria Capital Partners first reported a position in ClearPoint Neuro in Q2 2025 and held it in 4 quarters.
Epacria Capital Partners's ClearPoint Neuro position peaked at $256K in Q3 2025.
128 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q2 2026.

Based on Epacria Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.